Dr. Reddy's Laboratories Dirección

Dirección controles de criterios 2/4

El CEO de Dr. Reddy's Laboratories es Erez Israeli, nombrado en Apr 2018, tiene una permanencia de 6.58 años. posee directamente un 0.039% de las acciones de la empresa, con un valor de ₹390.85M. La antigüedad media del equipo directivo y de la junta directiva es de 6.6 años y 2.8 años, respectivamente.

Información clave

Erez Israeli

Chief Executive Officer (CEO)

₹197.1m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	6.6yrs
Participación del CEO	0.04%
Permanencia media de la dirección	6.6yrs
Promedio de permanencia en la Junta Directiva	2.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Erez Israeli en comparación con los beneficios de Dr. Reddy's Laboratories?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	₹53b
Jun 30 2024	n/a	n/a	₹56b
Mar 31 2024	₹197m	n/a	₹56b
Dec 31 2023	n/a	n/a	₹52b
Sep 30 2023	n/a	n/a	₹51b
Jun 30 2023	n/a	n/a	₹47b
Mar 31 2023	₹195m	n/a	₹45b
Dec 31 2022	n/a	n/a	₹36b
Sep 30 2022	n/a	n/a	₹31b
Jun 30 2022	n/a	n/a	₹30b
Mar 31 2022	₹127m	n/a	₹24b
Dec 31 2021	n/a	n/a	₹26b
Sep 30 2021	n/a	n/a	₹19b
Jun 30 2021	n/a	n/a	₹17b
Mar 31 2021	₹120m	n/a	₹17b
Dec 31 2020	n/a	n/a	₹21b
Sep 30 2020	n/a	n/a	₹15b
Jun 30 2020	n/a	n/a	₹19b
Mar 31 2020	₹195m	₹107m	₹19b
Dec 31 2019	n/a	n/a	₹16b
Sep 30 2019	n/a	n/a	₹27b
Jun 30 2019	n/a	n/a	₹21b
Mar 31 2019	₹123m	n/a	₹19b

Compensación vs. Mercado: La compensación total de Erez($USD2.33M) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD1.11M).

Compensación vs. Ingresos: La compensación de Erez ha sido consistente con los resultados de la empresa en el último año.

CEO

Erez Israeli (56 yo)

6.6yrs

Permanencia

₹197,090,000

Compensación

Mr. Erez Israeli, MBA has been Chief Executive Officer of Dr. Reddy's Laboratories Limited since August 1, 2019 and has been its Member of the Management Council since April 02, 2018. Mr. Israeli served as...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Gunupati Prasad	Co-Chairman	38.6yrs	₹186.28m	13.07% ₹ 129.9b
Kallam Reddy	Chairman of the Board & Member of the Management Council	31.8yrs	₹116.17m	13.61% ₹ 135.3b
Erez Israeli	CEO & Member of the Management Council	6.6yrs	₹197.09m	0.039% ₹ 390.8m
Mannam Venkatanarasimham	CFO & Member of the Management Council	less than a year	₹48.82m	0.0057% ₹ 56.4m
Krishna Venkatesh	Global Head of Quality and Pharmacovigilance & Member of the Management Council	less than a year	₹6.15m	sin datos
Deepak Sapra	CEO of API & Services & Member of Management Council	no data	₹41.90m	0.0027% ₹ 26.6m
Venkata Motupalli	CEO of Branded Markets - India & Emerging Countries and Member of Management Council	no data	₹82.74m	0.016% ₹ 156.4m
Archana Bhaskar	EVP, Head of Corporate Communications	7.4yrs	₹65.21m	0.0063% ₹ 63.1m
Sanjay Sharma	Executive VP	7.3yrs	₹66.05m	sin datos
Patrick Aghanian	CEO of European Generics & Member of Management Council	no data	₹63.09m	sin datos
Sushrut Kulkarni	Global Head of Integrated Product Development Organisation & Member of the Management Council	no data	₹55.63m	0.000020% ₹ 198.8k
Jayanth Sridhar	Global Head – Biologics & Member of the Management Council	no data	₹34.59m	sin datos

6.6yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 500124 es experimentado (6.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Gunupati Prasad	Co-Chairman	38.6yrs	₹186.28m	13.07% ₹ 129.9b
Kallam Reddy	Chairman of the Board & Member of the Management Council	31.8yrs	₹116.17m	13.61% ₹ 135.3b
R. Rajgopalan	Member of the Scientific Advisory Board	no data	₹8.36m	sin datos
Arun Kumar	Independent Director	2.3yrs	₹18.77m	sin datos
Shikha Sharma	Independent Director	5.8yrs	₹13.34m	sin datos
K. Reddy	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Leo Puri	Lead Independent Director	6.1yrs	₹17.10m	sin datos
Kodumudi Krishnan	Independent Director	2.8yrs	₹14.18m	sin datos
Sanjiv Mehta	Independent Director	less than a year	₹3.32m	sin datos
Alpna Seth	Independent Director	1.8yrs	₹8.25m	sin datos
Penny Wan	Independent Director	2.8yrs	₹17.10m	sin datos
Claudio Albrecht	Independent Director	1.5yrs	₹16.09m	sin datos

2.8yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de 500124 no se considera experimentada (2.8 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Dr. Reddy's Laboratories Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Dr. Reddy's and Nestle Health Science Appoints Mansi Khanna as Chief Operating Officer

Dr. Reddy's Laboratories Limited Announces Appointment of Milan Kalawadia as Chief Executive Officer, North America

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 29, 2024

Dr. Reddy's Laboratories Limited Announces Chief Financial Officer Changes

Dr. Reddy's Laboratories Limited Announces Executive Changes

Dr. Reddy's Laboratories Limited Appoints Sanjiv Mehta as A Non-Executive Independent Member of the Board

Recent updates

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories Limited Complaint Made Public in the United States District Court for the District of New Jersey

Dr. Reddy's Laboratories Limited to Report Q2, 2025 Results on Nov 05, 2024

Dr. Reddy's and Nestle Health Science Appoints Mansi Khanna as Chief Operating Officer

Price target increased by 7.3% to ₹6,611

Dr. Reddy's Laboratories Limited Approves Dividend for the Fiscal Year 2024

Dr. Reddy's Receives Positive CHMP Opinion from European Medicines Agency for Its Proposed Rituximab Biosimilar

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited to Report Q1, 2025 Results on Jul 27, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

Dr. Reddy's Laboratories Limited Announces Appointment of Milan Kalawadia as Chief Executive Officer, North America

Dividend of ₹40.00 announced

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 29, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

Dr. Reddy's Laboratories Limited Announces Chief Financial Officer Changes

Dr. Reddy's Laboratories Limited Announces Executive Changes

Dr. Reddy's Laboratories Limited to Report Q4, 2024 Results on May 07, 2024

Walgreen Co., Kroger Specialty Pharmacy, Inc. and CVS Pharmacy, Inc. File Complaint Against Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Dr. Reddy's Laboratories Limited Appoints Sanjiv Mehta as A Non-Executive Independent Member of the Board

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dr Reddy's Laboratories Reportedly Eyes Mega Brand in UK

Dr. Reddy's Laboratories Limited Announces Change in Management

Dr. Reddy's Laboratories Limited Announces Appointment of Sanjiv Mehta as Additional Director

Dr. Reddy's Laboratories Limited to Report Q3, 2024 Results on Jan 30, 2024

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed GMP and Pre-Approval Inspection

Dr. Reddy's Laboratories Ltd. Announces the Roll-Out of Nerivio in India

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

High number of new directors

Dr. Reddy's Laboratories Limited to Report Q2, 2024 Results on Oct 27, 2023

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Dr. Reddy's Laboratories Ltd. Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S

Dr. Reddy's Laboratories Limited Announces Resignation of Mukesh Rathi as Chief Information Officer

Dr. Reddy's Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2023

Price target increased by 7.7% to ₹5,388

Dr. Reddy's Laboratories Limited Announces Management Changes

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Announces Its Proposed Rituximab Biosimilar Application Acceptance for Review by USFDA, EMA and MHRA

Upcoming dividend of ₹40.00 per share at 0.8% yield

Dr. Reddy's Laboratories Limited to Report Q1, 2024 Results on Jul 26, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Completes Phase I Study (IV Route) of DRL_TC

Dr. Reddy's Laboratories Limited Reports Impairment Charges for the Fourth Quarter Ended March 31, 2023

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 27, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Announces the Launch of Regadenoson Injection 0.4 Mg/5 Ml in the U.S

Dr. Reddy's Laboratories Limited Announces the Launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Completes Full Set of Clinical Studies of Its Rituximab Biosimilar for Filing in the U.S., Europe

Dr. Reddy’S Launches In-House Palbociclib (Primcyv®) to Widen Access to High-Quality Breast Cancer Drug

Dr. Reddy's Laboratories Limited Announces Resignation of Allan Grant Oberman as an Independent Director

Dr. Reddy's Laboratories Provides Updates on Litigation

Dr. Reddy's Laboratories Limited to Report Q3, 2023 Results on Jan 25, 2023

Dr. Reddy s Laboratories Ltd. Announces Tocilizumab Biosimilar Candidate, DRL_TC, Successfully Met Its Primary and Secondary Endpoints in A Phase 1 Study

Consensus EPS estimates increase by 17%

Dr. Reddy's Laboratories Limited Announces Change in Directorate

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Appoints Mr. Arun Madhavan Kumar as an Independent Director

Dr. Reddy's Laboratories Limited to Report Q2, 2023 Results on Oct 28, 2022

Dr. Reddy's Laboratories Limited Informs Bruce L A Carter, Independent Director of the Company Has Ceased to Be A Director

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Dr. Reddy's Laboratories Limited Appoints Arun Madhavan Kumar as an Independent Additional Director

Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection, 3.5 Mg Single-Dose Vial in the U.S. Market

Dr. Reddy's Laboratories Limited Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed Pre-Approval Inspection At Formulations Manufacturing Facility FTO 11 in Srikakulam, Andhra Pradesh

Upcoming dividend of ₹30.00 per share

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Portfolio of four paediatric brands from Dr. Reddy's Laboratories Limited (BSE:500124) for INR 98 million.